← All companies

EIKN

Eikon Therapeutics, Inc.

EIKN Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗

$9.15

-0.47 -4.89%

Key statistics

from XBRL data in SEC filings

Market cap

$495M

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

$161M

Total assets

$851M

Gross margin

—

52-week range

$7.90 – $17.40

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Director or officer change Aug 3, 2026 8-K Director or officer change Jun 10, 2026 8-K Regulation FD disclosure; Other events Jun 1, 2026 10-Q Quarter ended 2026-03-31 May 11, 2026 8-K Results of operations (earnings release); Regulation FD disclosure May 11, 2026 8-K Results of operations (earnings release) Mar 30, 2026 10-K Fiscal year ended 2025-12-31 Mar 30, 2026 8-K Amended charter or bylaws Feb 6, 2026

Other filings

3 Jun 15, 2026 SCHEDULE 13G May 15, 2026 SCHEDULE 13G May 13, 2026 SCHEDULE 13G May 6, 2026 SCHEDULE 13G Apr 29, 2026 4 Mar 4, 2026 4 Mar 4, 2026 4 Mar 4, 2026 4 Mar 4, 2026 4 Mar 4, 2026 4 Mar 4, 2026 4 Mar 4, 2026 SCHEDULE 13G Feb 18, 2026 SCHEDULE 13D Feb 12, 2026 SCHEDULE 13G Feb 11, 2026 4 Feb 10, 2026 4 Feb 9, 2026 4 OWNERSHIP DOCUMENT Feb 6, 2026 4 Feb 6, 2026 4 Feb 6, 2026 4 Feb 6, 2026 S-8 Feb 6, 2026 424B4 Feb 5, 2026 3 Feb 4, 2026 3 Feb 4, 2026 3 Feb 4, 2026 3 Feb 4, 2026 3 Feb 4, 2026 3 Feb 4, 2026 3 Feb 4, 2026 3 Feb 4, 2026 3 Feb 4, 2026